Literature DB >> 1829916

Extrathymic malignancy in patients with myasthenia gravis.

Y Monden1, T Uyama, S Kimura, T Taniki.   

Abstract

The presence of extrathymic malignancies was investigated in 296 thymectomised myasthenia gravis (MG) cases. In 5 of the 296 cases, extrathymic malignant tumours were observed. 4 of the 5 cases had thymomatous MG. 3 cases had malignant fibrous histiocytoma. Extrathymic malignancies were observed more frequently in thymomatous MG than in non-thymomatous MG. 59 cases (60 tumours), including our 5 cases, who had MG and extrathymic malignant tumours were compiled from the literature. In the 60 extrathymic malignancies, leukaemia and reticulo-endothelial sarcoma were the most frequent types.

Entities:  

Mesh:

Year:  1991        PMID: 1829916     DOI: 10.1016/0277-5379(91)90179-h

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Risk factors for tumor occurrence in patients with myasthenia gravis.

Authors:  Antonietta Citterio; Ettore Beghi; Andrea Millul; Amelia Evoli; Renato Mantegazza; Carlo Antozzi; Fulvio Baggi; Ferdinando Cornelio; Luca Durelli; Marinella Clerico; Giovanni Piccolo; Vittorio Cosi
Journal:  J Neurol       Date:  2009-03-29       Impact factor: 4.849

3.  Myasthenia gravis as a presenting feature in a patient with lung cancer: A case report.

Authors:  Vahid Shaygannejad; Majid Ghasemi; Zahra Rajaee
Journal:  J Res Med Sci       Date:  2011-02       Impact factor: 1.852

4.  Myasthenia Gravis and Associated Diseases.

Authors:  Nikolina Tanovska; Gabriela Novotni; Slobodanka Sazdova-Burneska; Igor Kuzmanovski; Bojan Boshkovski; Goran Kondov; Marija Jovanovski-Srceva; Anita Kokareva; Rozalinda Isjanovska
Journal:  Open Access Maced J Med Sci       Date:  2018-03-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.